A5074321573- Lymphoma Diagnosis and Treatment
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Chronic Lymphocytic Leukemia Research
- Nuclear Structure and Function
- Cancer Immunotherapy and Biomarkers
- Cancer-related gene regulation
- Lung Cancer Treatments and Mutations
- RNA Research and Splicing
- Immune Cell Function and Interaction
- Mycobacterium research and diagnosis
- Chromatin Remodeling and Cancer
- 14-3-3 protein interactions
- Gene expression and cancer classification
- Cancer-related Molecular Pathways
- Single-cell and spatial transcriptomics
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Genetic factors in colorectal cancer
Mayo Clinic in Arizona
2020-2024
Mayo Clinic
2021-2024
WinnMed
2022
Arizona State University
2016
Mayo Clinic in Florida
2016
Mayo Clinic Hospital
2016
Follicular lymphoma (FL) is an indolent non-Hodgkin of germinal center origin, which presents with significant biologic and clinical heterogeneity. Using RNA-seq on B cells sorted from 87 FL biopsies, combined machine-learning approaches, we identify 3 transcriptional states that divide the biological ontology into inflamed, proliferative, chromatin-modifying states, relationship to prior GC cell phenotypes. When integrated whole-exome sequencing immune profiling, find each state was...
Abstract Recent genetic and molecular classification of DLBCL has advanced our knowledge disease biology, yet were not designed to predict early events guide anticipatory selection novel therapies. To address this unmet need, we used an integrative multiomic approach identify a signature at diagnosis that will high risk clinical failure. Tumor biopsies from 444 newly diagnosed analyzed by WES RNAseq. A combination weighted gene correlation network analysis differential expression was...
Abstract Non‐follicular low‐grade B‐cell lymphomas (LGBCL) are biologically diverse entities that share clinical and histologic features make definitive pathologic categorization challenging. While most patients with LGBCL have an indolent course, some experience aggressive disease, highlighting additional heterogeneity across these subtypes. To investigate the potential for shared biology subtypes, we performed RNA sequencing applied machine learning approaches identified five clusters of...
ABSTRACT PURPOSE 60-70% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients avoid events within 24 months diagnosis (EFS24) and the remainder have poor outcomes. Recent genetic molecular classification DLBCL has advanced our knowledge disease biology, yet were not designed to predict early guide anticipatory selection novel therapies. To address this unmet need, we used an integrative multiomic approach identify a signature at that will high risk clinical failure. PATIENTS AND...
This study sheds light on the pivotal role of oncoprotein DEK in B-cell lymphoma. We reveal expression correlates with increased tumor proliferation and inferior overall survival cases diagnosed low-grade lymphoma (LGBCL). also found significant correlation between copy number alterations LGBCL tumors, highlighting a novel mechanism pathogenesis that warrants additional exploration. To interrogate mechanistic lymphoma, we generated knockout cell line model, which demonstrated depletion...
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have poor prognosis. Genomic profiling has led broader understanding of the molecular drivers in DLBCL, but it is unknown how well current classifiers identify will experience primary treatment resistance (PTR). Using whole exome and RNA sequencing data from newly diagnosed DLBCL patients, we evaluated genomic landscape PTR compared non‐PTR DLBCL. We...
Background: While significant advances have been made in our understanding of FL biology, genomic studies to date primarily focused on prognostic (M7-FLIPI), pathological designation (Grade 1-3b), or transformation DLBCL. Conclusions from these are based either small cohorts targeted sequencing panels, with no larger-scale, integrated WES and RNAseq being performed. Together, this presents an opportunity for a comprehensive characterization FL. Using novel cohort 93 tumors, we explored the...
Abstract Introduction: In a pilot study, we recently described amplification of chromosome 9p24 encoding PD-L1, PD-L2, and JAK2 (the PDJ amplicon) in 29% early stage triple negative breast cancers (TNBC). Amplification was associated with poor DFS OS. The impact this amplicon on immune function is not known. Methods: Fresh frozen tumor samples from 36 subjects newly-diagnosed TNBC (stages I-III) were evaluated for copy number aberrations using DNA-based flow cytometry to enrich nuclei based...